cardiovascular diseases
Novo and Lilly in battle over blood sugar, weight and heart health
Over the past two days, Eli Lilly and Novo Nordisk have presented three studies that could shape future treatments for...
Big Pharma
Obesitas
Premium
Novo Nordisk shows its forefoot in clinical practice
The battle over the obesity market is constantly intensifying and the attacks are intensifying...
Big Pharma
Kina
Obesitas
Studieresultat
Fluicell CEO: “Type 1 diabetes is just the beginning of our growth journey”
Fluicell has developed a tissue platform based on high-resolution...
Intervju
Cereno Scientific's CBO on his new role
Cereno Scientific's clinical and preclinical programs in cardiovascular...
Intervju
Annexin Pharmaceuticals aims for "First-in-Class" with unique treatment for cardiovascular diseases
Biotechnology company Annexin Pharmaceuticals is developing a unique concept for...
Risk genes for cardiovascular disease identified in new study
A new study published in Science has identified...